US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Xbrane's CEO on the launch of Ximluci in Europe

Together with its partner STADA, the biosimilar company Xbrane Biopharma is currently in the process of launching Ximluci, a biosimilar to the reference drug Lucentis for the treatment of a serious eye disease. In connection with the BioStock Investor Meeting, the company's CEO Martin Åmark talked about the product launch, the plans for the upcoming US launch and the licensing plans for the oncology portfolio.Watch the interview with Martin Åmark at biostock.se: https://www.biostock.se/en/2023/03/xbranes-ceo-on-the-launch-of-ximluci-in-europe/ This is a press release from BioStock -

Vator Securities: Xbrane Biopharma: Pop up on your boards – “the third wave” of biosimilars is rather a tsunami.

Xbrane provides an exceptionally attractive exposure to the rapidly growing biosimilars market without the significant clinical and approval risk that is often present in biotech companies. 2019 proved to be a real tipping point with rapid uptake of the more recent biosimilar launches. It is nowadays  trivial to question the attractiveness of the biosimilar market opportunity; the interesting question is rather which players have the best fit to capture this opportunity. We believe that Xbrane stands well-positioned for this with Xlucane progressing through the low-risk pivotal phase III

There are no items matching the current filter
There are no more items matching the current filter
Back to top